Navigation Links
Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

LA JOLLA, Calif., Jan. 13 /PRNewswire/ -- Burnham Institute for Medical Research (Burnham) has signed an assay development and license agreement with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD). The agreement is Burnham's first broad-based partnership with a large pharmaceutical company.

Under this multi-year agreement, Burnham will provide J&JPRD with access to high-throughput assay screening technologies to investigate certain drug targets for inflammatory diseases. Financial terms were not disclosed.

"This collaboration offers great synergies," said Dr. John Reed, Burnham President and CEO, Professor and Donald Bren Presidential Chair. "Burnham has great expertise in finding new targets and screening compounds to identify chemical leads, and I believe this collaboration will foster the discovery of drug products with real clinical potential."

About Burnham Institute for Medical Research

Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest growing research institutes in the country. The Institute ranks among the top four institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies.

In September 2008, Burnham was awarded a prestigious six-year, $98 million Molecular Libraries Probe Production Centers Network (MLPCN) grant from the National Institutes of Health, and is one of four comprehensive small-molecule screening and discovery centers in the nation.

Burnham is a nonprofit, public benefit corporation. For more information, please visit

    Media Contacts:
    Josh Baxt
    Burnham Institute for Medical Research

    Martina Schwarzkopf, Ph.D.
    Russo Partners, LLC

SOURCE Burnham Institute for Medical Research
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
2. Cyntellect to Collaborate With the Burnham Institute for Medical Research
3. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
4. Neurobiological Technologies Announces Suspension of Viprinex Development
5. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
6. Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services
7. Varian, Inc. Announces Online Experience
8. Victhom announces the completion of the second phase of the apnea therapy development
9. The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates
10. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
11. Abbott Announces Earnings Guidance for 2009
Post Your Comments:
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
Breaking Biology Technology:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):